Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5041 in Metastatic Castration-resistant Prostate Cancer
NCT06830850Phase 1Active, not recruiting
- Sponsor
- Atridia Pty Ltd
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-5041 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Atridia Pty Ltd. Primary endpoint: Incidence and severity of adverse events at 1 year. Started Jun 2025; status: active, not recruiting.
02
Drugs
HRS-5041
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06830850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830850.